Eli Lilly's Jaypirca Secures Fourth Positive CLL Phase 3 Readout Jaypirca met its primary endpoint. The drug showed fixed-duration efficacy. This is an industry first for CLL. Lilly's profile in CLL strengthens. Eli Lilly announced positive Phase 3 results for Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia (CLL). The BRUIN CLL-322 trial achieved its primary endpoint, demonstrating superior progression-free survival (PFS) as a fixed-duration treatment. This marks Jaypirca's fourth successful Phase 3 readout, solidifying its clinical efficacy across multiple CLL settings. The metric triggering this event was the statistically significant improvement in PFS. This positive outcome positions Jaypirca for potential label expansion. Under FDA regulations, these data support a supplemental New Drug Application (sNDA). EMA approval processes will likely follow a similar trajectory, with Lilly submitting a Type II variation. The fixed-duration aspect is a significant differentiator, potentially offering patients a treatment break. This aligns with 21 CFR Part 314 for new drug applications and post-market changes. The positive data intensifies competition in the CLL market. Jaypirca now offers a unique fixed-duration option, challenging established BTK inhibitors like AbbVie/Johnson & Johnson's Imbruvica and AstraZeneca's Calquence. This could shift market share, benefiting Lilly. Expect an sNDA submission to the FDA by Q3 2026, potentially leading to a new treatment paradigm for CLL patients.